Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IVA
IVA logo

IVA Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
5.980
Open
5.930
VWAP
5.80
Vol
179.44K
Mkt Cap
1.19B
Low
5.695
Amount
1.04M
EV/EBITDA(TTM)
--
Total Shares
207.65M
EV
939.24M
EV/OCF(TTM)
--
P/S(TTM)
--
Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Show More

Events Timeline

(ET)
2025-11-13
09:31:35
Inventiva Prices 32.47M Share Spot Secondary at $3.85
select
2025-11-12 (ET)
2025-11-12
16:46:09
Inventiva Announces Offering of $125M in American Depositary Shares
select

News

Benzinga
2.0
2025-11-28Benzinga
Tilray Brands, SuperX AI Technology, and Other Major Stocks Decline in Friday's Pre-Market Trading
  • U.S. Stock Futures: U.S. stock futures rose this morning, with Dow futures increasing by approximately 50 points on Friday.

  • Tilray Brands Inc: Shares of Tilray Brands Inc fell 15% in pre-market trading after announcing a one-for-10 reverse stock split, set to take effect on December 1.

  • Other Stocks Declining: Several other stocks also experienced declines in pre-market trading, including Inventiva ADR (-7.4%), Anglogold Ashanti PLC (-5.5%), and Lexicon Pharmaceuticals Inc (-5%).

  • Market Movements: SuperX AI Technology Ltd saw a significant drop of 3.9% after a previous surge, while Gold Fields Ltd and Abacus Global Management Inc also reported declines following recent gains.

Benzinga
2.0
2025-11-28Benzinga
Heartbeam Shares Surge Approximately 43%; Check Out 20 Stocks Making Moves in Premarket Trading
  • Heartbeam Inc's Stock Surge: Heartbeam Inc's shares rose 43.3% in pre-market trading after announcing its regulatory strategy following the FDA's Not Substantially Equivalent decision on its Electrocardiogram Synthesis Software, with plans for an appeal or 510(k) resubmission.

  • Other Notable Gainers: Several stocks saw significant gains in pre-market trading, including SMX PLC (+73.1%), Zenta Group (+26.7%), and Waton Financial (+21.1%), reflecting a positive trend in the market.

  • Major Losers: FBS Global Ltd experienced a sharp decline of 24.3%, while Tilray Brands fell 15% after announcing a reverse stock split, indicating volatility among certain stocks.

  • Market Overview: The pre-market trading session showed mixed results, with notable gains for some companies and significant losses for others, highlighting the fluctuating nature of the stock market.

Globenewswire
9.0
2025-11-28Globenewswire
Inventiva's Shareholders' Meeting Approves All Resolutions Except for the 5th One
  • Shareholder Meeting Outcome: During the shareholders' meeting on November 27, 2025, all resolutions were approved except for the 5th, indicating strong shareholder support for the company's governance and future strategic direction.
  • Voting Participation: A total of 441 shareholders participated, representing 56.432% of the voting rights, highlighting shareholder engagement and enhancing the company's transparency in the capital market.
  • 5th Resolution Rejected: The 5th resolution was rejected with only 41.642% support, reflecting shareholders' cautious stance towards the board's proposal, which may impact the company's future capital structure and employee incentive plans.
  • CEO Compensation Policy Approved: The shareholders unanimously approved the CEO's compensation policy, demonstrating trust in management, which could help attract and retain key talent to drive the company's growth.
Benzinga
2.0
2025-11-24Benzinga
Novo Nordisk, Waldencast, and Other Major Stocks Decline in Pre-Market Trading on Monday
  • U.S. Stock Futures: U.S. stock futures are up, with Nasdaq futures increasing by about 100 points on Monday morning.

  • Novo Nordisk Decline: Shares of Novo Nordisk fell 9.3% in pre-market trading after Phase 3 trial data indicated GLP-1 drugs did not significantly reduce Alzheimer’s disease progression.

  • Other Stocks Dropping: Several other stocks also saw declines in pre-market trading, including Geospace Technologies down 13.7% and Inventiva down 6.1%.

  • Market Overview: Overall, various companies experienced significant drops in their stock prices following recent trading updates and earnings reports.

Benzinga
9.5
2025-11-24Benzinga
LexinFintech Shares Surge Over 15%; Check Out 20 Stocks Making Moves in Premarket Trading
  • LexinFintech Holdings Performance: LexinFintech Holdings Ltd reported a significant increase in quarterly earnings, rising to 43 cents per share from 28 cents a year ago, despite a drop in sales to $367.580 million from $521.851 million. The stock surged 15.3% in pre-market trading.

  • Other Gainers in Pre-Market Trading: Several stocks saw notable increases in pre-market trading, including Inspire Veterinary Partners Inc (+54.4%), VisionSys AI Inc (+43.4%), and JX Luxventure Group Inc (+36.2%).

  • Losers in Pre-Market Trading: Conversely, stocks like Clearside Biomedical Inc (-50.3%), Shuttle Pharmaceuticals Holdings Inc (-15%), and XChange TEC.INC (-14%) experienced significant declines in pre-market trading.

  • Market Overview: The article provides a snapshot of various stocks' performances in pre-market trading, highlighting both gainers and losers, along with specific percentage changes.

Benzinga
2.0
2025-10-29Benzinga
Major Stocks Including Mondelez International, Stride, and Varonis Systems Decline in Wednesday's Pre-Market Trading
  • U.S. Stock Futures: U.S. stock futures showed mixed results, with Dow futures dropping approximately 100 points on Wednesday.

  • Mondelez International Earnings: Mondelez International's shares fell 5.8% in pre-market trading after the company lowered its FY2025 earnings guidance despite reporting quarterly earnings and sales that exceeded analyst expectations.

  • Other Stocks Declining: Several other companies, including Stride Inc, Varonis Systems Inc, and Akebia Therapeutics Inc, experienced significant declines in pre-market trading due to disappointing sales guidance or earnings reports.

  • Market Reactions: The overall market sentiment was negative, with multiple stocks, including Caesars Entertainment and Enphase Energy, also reporting earnings below estimates, contributing to their respective declines.

Wall Street analysts forecast IVA stock price to rise
6 Analyst Rating
Wall Street analysts forecast IVA stock price to rise
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
11.00
Averages
15.67
High
26.00
Current: 0.000
sliders
Low
11.00
Averages
15.67
High
26.00
Truist
initiated
$13
AI Analysis
2026-03-18
Reason
Truist
Price Target
$13
AI Analysis
2026-03-18
initiated
Reason
Truist initiated coverage of Inventiva with a Buy rating and $13 price target. Lead asset lanifibranor has a unique mechanism and profile among metabolic dysfunction-associated steatohepatitis therapies in development that could make it "an ideal choice" for a niche group of MASH patients with diabetes, the analyst tells investors. Near-term Phase 3 data due in the second half of the year "could result in up to +100% upside from current levels," contends the analyst, who estimates base case third-line use in MASH F2/F3 supports $2.3B worldwide peak adjusted revenue.
Barclays
Overweight
initiated
$18
2026-01-27
Reason
Barclays
Price Target
$18
2026-01-27
initiated
Overweight
Reason
Barclays initiated coverage of Inventiva with an Overweight rating and $18 price target. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for IVA
Unlock Now

Valuation Metrics

The current forward P/E ratio for Inventiva SA (IVA.O) is -2.78, compared to its 5-year average forward P/E of -4.87. For a more detailed relative valuation and DCF analysis to assess Inventiva SA's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.87
Current PE
-2.78
Overvalued PE
1.03
Undervalued PE
-10.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.91
Current EV/EBITDA
-6.99
Overvalued EV/EBITDA
0.99
Undervalued EV/EBITDA
-10.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
44.37
Current PS
97.84
Overvalued PS
83.61
Undervalued PS
5.12

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

stocks under 10 expected to gap up today
Intellectia · 26 candidates
Price: $1.00 - $10.00Volume: >= 200,000Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEGap Pattern: GapUpPre Market Price Change: >= $3.00
Ticker
Name
Market Cap$
top bottom
JZXN logo
JZXN
Jiuzi Holdings Inc
1.66M
CDIO logo
CDIO
Cardio Diagnostics Holdings Inc
3.89M
BOXL logo
BOXL
Boxlight Corp
1.24M
TALK logo
TALK
Talkspace Inc
651.03M
ELAB logo
ELAB
PMGC Holdings Inc
1.46M
MOB logo
MOB
Mobilicom Ltd
58.61M
Should I Buy ppta tomorrow
Intellectia · 77 candidates
Sector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical ResearchMarket Cap Category: smallWeek Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
CRVS logo
CRVS
Corvus Pharmaceuticals Inc
1.65B
RAPT logo
RAPT
RAPT Therapeutics Inc
1.60B
ACRS logo
ACRS
Aclaris Therapeutics Inc
478.89M
LXRX logo
LXRX
Lexicon Pharmaceuticals Inc
566.90M
CTMX logo
CTMX
CytomX Therapeutics Inc
896.31M
VOR logo
VOR
Vor Biopharma Inc
700.06M
what stock should I buy now
Intellectia · 157 candidates
Market Cap: >= 1000.00MRelative Vol: >= 1.50Week Price Change Pct: >= $5.00
Ticker
Name
Market Cap$
top bottom
BH.A logo
BH.A
Biglari Holdings Inc
1.53B
LCII logo
LCII
LCI Industries
3.66B
CNTA logo
CNTA
Centessa Pharmaceuticals PLC
3.39B
ALM logo
ALM
Almonty Industries Inc
2.60B
DCOM logo
DCOM
Dime Community Bancshares Inc
1.44B
QGEN logo
QGEN
Qiagen NV
11.51B
reduce to top 5
Intellectia · 35 candidates
Analyst Consensus: Strong BuyRelative Vol: >= 1.50Target Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
VNOM logo
VNOM
Viper Energy Inc
14.18B
CIFR logo
CIFR
Cipher Mining Inc
7.00B
ALKS logo
ALKS
Alkermes Plc
5.59B
CGON logo
CGON
CG Oncology Inc
4.61B
CRC logo
CRC
California Resources Corp
4.37B
ALH logo
ALH
Alliance Laundry Holdings Inc
4.27B
what pharma stock good buy for next week
Intellectia · 16 candidates
Relative Vol: >= 2Weekly Average Turnover: >= 1,000,000Moving Average Relationship: PriceAboveMA5Week Price Change Pct: >= $5.00
Ticker
Name
Market Cap$
top bottom
QGEN logo
QGEN
Qiagen NV
11.51B
IBRX logo
IBRX
Immunitybio Inc
6.82B
CNTA logo
CNTA
Centessa Pharmaceuticals PLC
3.39B
KNSA logo
KNSA
Kiniksa Pharmaceuticals International PLC
3.17B
IMCR logo
IMCR
Immunocore Holdings PLC
1.78B
CRVS logo
CRVS
Corvus Pharmaceuticals Inc
1.65B
best medical 3 stocks to buy under $20
Intellectia · 22 candidates
Market Cap: >= 500.00MPrice: <= $20.00Beta: LowRiskWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
TAK logo
TAK
Takeda Pharmaceutical Co Ltd
51.17B
HLN logo
HLN
Haleon PLC
45.60B
KVUE logo
KVUE
Kenvue Inc
33.30B
VTRS logo
VTRS
Viatris Inc
15.03B
RDY logo
RDY
Dr Reddy's Laboratories Ltd
11.06B
BAX logo
BAX
Baxter International Inc
10.13B
which stocks show a great upside
Intellectia · 35 candidates
Analyst Consensus: Strong BuyBeta: LowRiskWeekly Average Turnover: >= 1,000,000Target Price Upside Potential: MoreAbovePriceMonth Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
LNG logo
LNG
Cheniere Energy Inc
44.62B
VNOM logo
VNOM
Viper Energy Inc
14.18B
TTEK logo
TTEK
Tetra Tech Inc
9.59B
PRAX logo
PRAX
Praxis Precision Medicines Inc
8.57B
CORZ logo
CORZ
Core Scientific Inc
5.64B
ALKS logo
ALKS
Alkermes Plc
5.59B

Whales Holding IVA

P
Paradigm Biocapital Advisors LP
Holding
IVA
+6.14%
3M Return
A
Artal Group S.A.
Holding
IVA
+0.12%
3M Return
P
Perceptive Advisors LLC
Holding
IVA
-0.06%
3M Return
B
BVF Partners L.P.
Holding
IVA
-1.91%
3M Return
Q
Qatar Holding LLC
Holding
IVA
-6.81%
3M Return
N
New Enterprise Associates, Inc.
Holding
IVA
-8.83%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Inventiva SA (IVA) stock price today?

The current price of IVA is 5.72 USD — it has decreased -6.08

What is Inventiva SA (IVA)'s business?

Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

What is the price predicton of IVA Stock?

Wall Street analysts forecast IVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IVA is15.67 USD with a low forecast of 11.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Inventiva SA (IVA)'s revenue for the last quarter?

Inventiva SA revenue for the last quarter amounts to NaN USD, decreased

What is Inventiva SA (IVA)'s earnings per share (EPS) for the last quarter?

Inventiva SA. EPS for the last quarter amounts to USD, decreased

How many employees does Inventiva SA (IVA). have?

Inventiva SA (IVA) has 123 emplpoyees as of March 29 2026.

What is Inventiva SA (IVA) market cap?

Today IVA has the market capitalization of 1.19B USD.